| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/26/2006 | EP1650315A1 Vibrio cholerae strains VCUSM1 and VCUSM4, method of producing same, and vaccine derivatives thereof |
| 04/26/2006 | EP1650312A2 Functional assay of high-density lipoprotein |
| 04/26/2006 | EP1650310A1 Recombinant avian adenovirus vector |
| 04/26/2006 | EP1650309A1 Lentiviral vectors for the preparation of immunotherapeutical compositions |
| 04/26/2006 | EP1650308A1 Nucleic acid sequences encoding proteins capable of associating into a virus-like particle |
| 04/26/2006 | EP1650225A1 Hetero type pentamer recombinant vaccine |
| 04/26/2006 | EP1650221A2 Novel compounds |
| 04/26/2006 | EP1650220A2 Anti-VEGF antibodies |
| 04/26/2006 | EP1650219A1 Human toll homologues |
| 04/26/2006 | EP1649870A2 Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
| 04/26/2006 | EP1649869A1 Combination of a recombinant mycobacterium and a biologically active agent as a vaccine |
| 04/26/2006 | EP1649868A1 IL-12 as an adjuvant for Bordetella pertussis vaccines |
| 04/26/2006 | EP1649861A2 Adjuvant compositions comprising a mineral salt and another immunostimulating compound |
| 04/26/2006 | EP1649287A1 Evaluation of adjuvanted vaccines |
| 04/26/2006 | EP1649053A2 Characterization of the earliest stages of the severe acute respiratory syndrome (sars) virus and uses thereof |
| 04/26/2006 | EP1649028A2 Adenoviral vector-based vaccines |
| 04/26/2006 | EP1649011A2 Novel keratinocyte culturing method and the use thereof |
| 04/26/2006 | EP1648998A2 Specific binding agents to hepatocyte growth factor |
| 04/26/2006 | EP1648937A1 Product and composition containing a concholepas concholepas hemocyanin (cch) subunit a, and a method of use thereof |
| 04/26/2006 | EP1648935A2 Antagonists and agonists of ldcam and methods of use |
| 04/26/2006 | EP1648927A1 Soluble fragments of the sars-cov spike glycoprotein |
| 04/26/2006 | EP1648913A2 Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
| 04/26/2006 | EP1648512A2 Anti-cd19 antibodies |
| 04/26/2006 | EP1648509A2 Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
| 04/26/2006 | EP1648506A1 Method for treating synovial sarcoma |
| 04/26/2006 | EP1648505A1 Quil a fraction with low toxicity and use thereof |
| 04/26/2006 | EP1648504A2 Adjuvant combinations of liposomes and mycobacterial lipids for immunization compositions and vaccines |
| 04/26/2006 | EP1648503A2 Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases |
| 04/26/2006 | EP1648502A2 Hcv vaccines |
| 04/26/2006 | EP1648501A1 Hybrid toxins comprising shiga-like toxin subunits fused to escherichia coli heat labile enterotoxin subunits and vaccines thereof |
| 04/26/2006 | EP1648500A2 Immunogenic compositions for streptococcus pyogenes |
| 04/26/2006 | EP1648499A2 P. aeruginosa mucoid exopolysaccharide specific binding peptides |
| 04/26/2006 | EP1648498A1 Microsome vaccine |
| 04/26/2006 | EP1648488A2 Human mast cell-expressed membrane protein |
| 04/26/2006 | EP1648428A2 Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer |
| 04/26/2006 | EP1648427A2 Compositions and methods including a recombinant human mab that promotes cns remyelination |
| 04/26/2006 | EP1648388A2 Novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax |
| 04/26/2006 | EP1648379A2 Vaccines using pattern recognition receptor-ligand:lipid complexes |
| 04/26/2006 | EP1421377B1 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 04/26/2006 | EP1402039B1 MUTANT FORMS OF EtxB AND CtxB AND THEIR USE AS CARRIERS |
| 04/26/2006 | EP1368478B1 Polypeptide inducing hiv-neutralising antibodies |
| 04/26/2006 | EP1326634B1 Vaccine composition comprising an antigen and a peptide having adjuvant properties |
| 04/26/2006 | EP1303286B1 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
| 04/26/2006 | EP1218514B1 Designing immunogens |
| 04/26/2006 | EP1187918B1 Tek antagonists |
| 04/26/2006 | EP1105466B1 Process for purifying human papillomavirus virus-like particles |
| 04/26/2006 | EP1049788B1 Protein expression in baculovirus vector expression systems |
| 04/26/2006 | EP1009829B1 Adipocyte-specific protein homologs |
| 04/26/2006 | EP1002108B1 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
| 04/26/2006 | EP0983302B1 Mutated ScFv-Fragment of the OKT-3 antibody |
| 04/26/2006 | EP0908466B1 Anti-human lect2 antibody, cells producing the same, and method and kit for assaying the same |
| 04/26/2006 | EP0850305B1 Compounds and methods for diagnosis of tuberculosis |
| 04/26/2006 | EP0811057B1 Viral preparations, vectors, immunogens, and vaccines |
| 04/26/2006 | EP0784686B1 Herpes simplex virus glycoprotein d variants |
| 04/26/2006 | CN1764719A MELAN-A peptide analogue-virus-like-particle conjugates |
| 04/26/2006 | CN1764478A Anti-cancer anthracycline drug-antibody conjugates |
| 04/26/2006 | CN1764476A Composition and method for the treatment and prevention of enteric bacterial infections |
| 04/26/2006 | CN1764475A Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
| 04/26/2006 | CN1764474A Immunogenic composition and methods |
| 04/26/2006 | CN1764473A Use of alum and a Th1 immune response inducing adjuvant for enhancing immune responses |
| 04/26/2006 | CN1764472A Injectable vaccines against multiple meningococcal serogroups |
| 04/26/2006 | CN1764455A Pharmaceutical composition comprising a macrolide immunomodulator. |
| 04/26/2006 | CN1764375A Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease |
| 04/26/2006 | CN1763205A Recombinant chicken Marek's disease virus transfer vector and application thereof |
| 04/26/2006 | CN1763199A Thioredoxin gene of Schistosoma japonicum (Chinese Mainland Strain) and its cloning expression method and application |
| 04/26/2006 | CN1763181A Vaccine against mumps containing a JERYL-LYNN virus strain |
| 04/26/2006 | CN1763174A Culture and collection of dermatophagoides pteronyssinus and method for preparing its allergen diagnosis and treatment preparation |
| 04/26/2006 | CN1763105A Fusion protein for stimulating organism to produce FMDV antibody and its coding gene and uses |
| 04/26/2006 | CN1763101A Antibody of human acidophil chemotactic factor receptor 3 and its preparation method and uses |
| 04/26/2006 | CN1763097A Polypeptide variants with altered effector function |
| 04/26/2006 | CN1763096A Animal composite immune globulin production method |
| 04/26/2006 | CN1762492A CD40 binding molecules and CTL peptides uses in pharmic composition for treating tumors |
| 04/26/2006 | CN1762491A Use of BCG as adjuvant of active protein activating cytotoxic T-lymphocyte |
| 04/26/2006 | CN1762490A Tumor antigen based on products of the tumor suppressor gent WT1 |
| 04/26/2006 | CN1253572C Isolated peptides which bind to HLA-C molecules and uses thereof |
| 04/26/2006 | CN1253551C Genetically modified tumor-targeted bacteria with reduced virulence |
| 04/26/2006 | CN1253469C Antigenic determinant polypeptide of human tumor-testis antigen HCA587 and use thereof |
| 04/26/2006 | CN1253220C Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| 04/26/2006 | CN1253208C Use of antibodies against CD2O for treatment of graft versus host disease |
| 04/26/2006 | CN1253207C Split enveloped virus preparation |
| 04/26/2006 | CN1253206C Method for obtaining antigenic aggregates and use thereof in formulations |
| 04/26/2006 | CN1253205C 疫苗 Vaccine |
| 04/25/2006 | US7034141 The packaging systems are based on the expression of split-helper functions by coinfecting cells with recombinant vectors, such as recombinant poxvirus vectors |
| 04/25/2006 | US7034132 Nucleic acid sequences that encode G- coupled protein-receptor related polypeptides; diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving these human nucleic acids and proteins |
| 04/25/2006 | US7034121 Antibodies against CTLA4 |
| 04/25/2006 | US7034108 Mimotopes of hypervariable region 1 of the E2 glycoprotein of HCV and uses thereof |
| 04/25/2006 | US7034107 High throughput assays for the proteolytic activities of clostridial neurotoxins |
| 04/25/2006 | US7034106 Pro1159 polypeptides |
| 04/25/2006 | US7033813 Deactivation vaccine; using critical temperature, critical pressure solvent |
| 04/25/2006 | US7033799 Haemophilus adherence and penetration proteins |
| 04/25/2006 | US7033798 Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragment |
| 04/25/2006 | US7033797 for identification and vaccination of human papillomavirus; |
| 04/25/2006 | US7033796 cloned from cDNA library of human liver carcinoma cell line using PCR amplification; host cells |
| 04/25/2006 | US7033795 FabK variant |
| 04/25/2006 | US7033767 Genes regulating programmed cell death |
| 04/25/2006 | US7033755 Diagnostics and therapeutics for glaucoma |
| 04/25/2006 | US7033596 Transformant for screening of inhibitors for human immunodeficiency virus |
| 04/25/2006 | US7033595 Pseudotyped retroviruses and stable cell lines for their production |
| 04/25/2006 | US7033594 Method of treatment using ligand-immunogen conjugates |
| 04/25/2006 | US7033593 Immunogen comprising an HIV envelope protein, a ligand and H2 peptide |